- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01613898
Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis (CTX)
The aim of the proposed study is to evaluate the risk for cardiovascular disease and 'atherogenic' features of the serum in CTX and to determine preclinical atherosclerosis. The study will include an extensive assessment of lipoprotein profile and carotid artery intima-media thickness (cIMT) measurement.
Lipid and lipoprotein profiles will include novel tests such as direct measurements of apolipoprotein A1,B,C2,C3 plasma levels, lipoprotein (a) levels, highly sensitive C-reactive protein levels and PLAC test that measures the levels of lipoprotein-associated phospholipase A2-a vascular-specific inflammatory enzyme implicated in the formation of atherosclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Protocol 09-2009 EVALUATION OF CAROTID IMT AND ATHEROGENIC RISK FACTORS IN PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS
ABSTRACT Cerebrotendinous xanthomatosis (CTX) is a rare disease characterized by xanthomatous lesions in many tissues, mainly in the brain. Mutation in the gene of sterol 27-hydroxylase-an enzyme in bile acid synthesis causes CTX. The impaired synthesis of chenodeoxycholic acid from cholesterol results in elevated plasma and bile cholestanol.
The natural course of CTX is progressive neurologic deterioration from childhood through adulthood leading to diffuse damage of the central and peripheral nervous systems and eventually to death.
Cardiovascular involvement in CTX is probably high: different clinical manifestations of cardiovascular disease (CVD) were reported in 10.4% of patients with CTX. The precise mechanism of the atherosclerosis in CTX is unknown and may be related to cholestanol accumulation in the vascular subendothelial space.
Abnormalities in the lipoprotein profile were not described in the literature, and cholesterol levels are within normal limits in CTX. Extensive evaluation for CVD risk factors in the CTX patient group have not been conducted apart from a small number of publications.
The aim of the proposed study is to evaluate the risk for cardiovascular disease and 'atherogenic' features of the serum in CTX and to determine preclinical atherosclerosis. The study will include an extensive assessment of lipoprotein profile and carotid artery intima-media thickness (cIMT) measurement.
Lipid and lipoprotein profiles will include novel tests such as direct measurements of apolipoprotein A1,B,C2,C3 plasma levels, lipoprotein (a) levels, highly sensitive C-reactive protein levels and PLAC test that measures the levels of lipoprotein-associated phospholipase A2-a vascular-specific inflammatory enzyme implicated in the formation of atherosclerosis.
This would be the first attempt to conduct such an extensive evaluation in the CTX patients group.
Research Plan:
Study Design and Methods
Subjects The study population will constitute of all 17 CTX diagnosed patients that will be recruited from the CTX outpatient clinic at the Parkinson's disease and movement disorders Clinic in the Sagol Neuroscience Center, at the Chaim Sheba Medical Center. Patients will be contacted by phone and by mail and be invited to participate.
Control group will consist of age and gender matched healthy individuals. All patients or their legal guardians will sign an informed consent.
Detailed Plan of the Study
All study participants will undergo an evaluation that will include one clinic visit :
Visit 1
- A detailed medical history, including demographic data, past medical history, smoking history, use of medications, and family history of dyslipidemia and atherosclerotic cardiovascular disease.
- Physical examination including height and weight measurements, blood pressure, BMI, waist and hip circumference.
Blood samples
Fasting Lipid profile:
Total cholesterol, HDL-cholesterol, direct LDL-cholesterol and Triglycerides (TG)
- Apolipoprotein profile:
- apolipoprotein A1
- apolipoprotein B
- apolipoprotein C2
- apolipoprotein C3
c. lipoprotein (a) [Lp(a)] d. C-Reactive Protein -hsCRP e. Lipoprotein-associated Phospholipase A2 (Lp-PLA2) f. Apo E genotyping g. Plasma cholestanol level h. Fasting plasma glucose and Insulin
- 12 lead electrocardiogram (ECG)
- cIMT assessment.
Methods:
- Laboratory studies
- Blood samples will be taken after an overnight fast
- Total cholesterol, HDL-cholesterol and TG in plasma will be determined by colorimetric enzymatic procedures (Olympus, Ireland).
- Apolipoprotein A1, B, C2, C3 and Lp(a) serum concentrations will be determined by the immuno-turbidimetric procedure . (Olympus, Ireland).
- Direct LDL- will be determined by enzymatic color test. (Olympus, Ireland).
- HsCRP- will be determined by turbidimetric immunoassay(Olympus, Ireland)
- Lp-PLA2 (PLAC® Test) - The PLAC Test measures Lp-PLA2 (lipoprotein-associated phospholipase A2), a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. Turbidimetric Immunoassay for the Quantitative Determination of Lp-PLA2 in Human Plasma (diaDexus, Inc. CA .USA) The Olympus AU 400 autoanalyzer will be used for all the above-mentioned measurements.
- Apo E genotyping- Apo E genotypes of genomic DNA from blood will be determined by a single nucleotide primer extension Elisa assay. (Pronto Diagnostics, Tel Aviv, Israel )
- Plasma cholestanol level- will be measured by high-performance liquid chromatography with ultraviolet detection (Halperin et al , ref 10 )
- Glucose -will be measured by the glucose oxidase method (Olympus AU2700, Hamburg, Germany).
- Insulin- will be measured by a chemiluminiscent immunometric method (Immulite 2000, Diagnostic Products Corporation, Los Angeles, CA).
- ECG-12 lead electrocardiogram will be done. (Mac 1100,GE medical systems, Germany)
Carotid artery Intima-media thickness : Patients will undergo a color-coded duplex examination of neck vessels using a 10MHz linear array ultrasound (Hitachi medical corporation, Tokyo, Japan). IMT will be evaluated on the common carotid arteries (CCAs) over ≈1.5 cm proximal to the flow divider, according to standardized guidelines. In brief, IMT will be measured at the thickest plaque-free point on the near and far walls with a specially designed computer program. CCA wall thickness will be defined as the mean of the maximum wall thickness of the near and far walls bilaterally. Ultrasound images of the distal 1 cm of the far wall of each common carotid artery will be obtained and compared with values from a normative data set (age and sex matched). Mean CIMT values from the far walls of the right and left common carotid arteries will be reported
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Tel Hashomer, Israel, 52621
- Recruiting
- The Bert W. Strassburger Lipid Center
-
Principal Investigator:
- Hofit Cohen, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The study population will constitute of all 17 CTX diagnosed patients
Exclusion Criteria:
- Non CTX patients
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CTX Group
|
Blood tests
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predisposition of CTX patients for pro-atherogenic features as evaluated by lipid and lipoproteins plasma profiles, and blood chemical assessment. Preclinical atherosclerosis in CTX patients as determined by Carotid artery Intima-media thickness 1.
Time Frame: 3 years
|
The predisposition of the serum of CTX patients to be pro-atherogenic will be evaluated by detailed lipid and lipoproteins plasma profiles, and blood chemical assessment of specific inflammatory pro-atherogenenic features. IMT Presence of preclinical atherosclerosis will be determined by Carotid artery Intima-media thickness as a marker of risk for cardiovascular disease. |
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hofit Cohen, MD, The Bert W. Strassburger Lipid Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHEBA-09-7393-HC-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebrotendinous Xanthomatosis (CTX)
-
TRPHARMKlinar CRO; Düzen Laboratories GroupTerminatedCTX - Cerebrotendinous XanthomatosisTurkey
-
Travere Therapeutics, Inc.UnknownCerebrotendinous Xanthomatosis (CTX)United States
-
Mirum Pharmaceuticals, Inc.Completed
-
Humanis Saglık Anonim SirketiCompleted
-
Leadiant Biosciences Ltd.CompletedCerebrotendinous Xanthomatoses
-
Leadiant Biosciences, Inc.Not yet recruitingCerebrotendinous Xanthomatoses
-
TRPHARMKlinar CRO; Damagen Genetic Diagnostic CenterEnrolling by invitationXanthomatosis, CerebrotendinousTurkey
-
US Department of Veterans AffairsWithdrawn
-
National Center for Research Resources (NCRR)Oregon Health and Science UniversityUnknownCerebrotendinous XanthomatosisUnited States
-
TRPHARMKlinar CRO; Düzen Laboratories GroupRecruitingCerebrotendinous XanthomatosisTurkey
Clinical Trials on Blood tests
-
Calimmune, Inc.Active, not recruitingHIV-1 Infection | Receipt of Cal-1 Modified Hematopoietic Cellular ProductsUnited States
-
HaEmek Medical Center, IsraelCompleted
-
University of Colorado, DenverTerminatedVenous ThromboembolismUnited States
-
The Netherlands Cancer InstituteBayerCompletedBone Metastases | Prostate Cancer MetastaticNetherlands
-
Centre Hospitalier Universitaire, AmiensCompletedCardiovascular AbnormalitiesFrance
-
University of SussexUniversity of OxfordRecruiting
-
Cwm Taf University Health Board (NHS)Cardiff University; Imperial College London; University of OxfordCompletedDiabetes Mellitus, Type 1 | SARS-CoV2 InfectionUnited Kingdom
-
Aga Khan UniversityCompletedOrthopedic Disorder
-
Carmel Medical CenterCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Alaunos Therapeutics; National Center for Research...RecruitingRetroviridae Infections | CancerUnited States